Prescrire Int. 2015 Sep;24(163):207.
Overall, VEGF inhibitors administered by intravitreal injection have a similar harm-benefit balance. However, a publicly funded trial has shown that aflibercept is more effective than ranibizumab and bevacizumab in patients with marked loss of visual acuity.
总体而言，通过玻璃体腔内注射给予的血管内皮生长因子（VEGF）抑制剂具有相似的利弊平衡。然而，一项公共资助的试验表明，在视力显著丧失的患者中，阿柏西普比雷珠单抗和贝伐单抗更有效。
